NCT07073950 - A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Chronic Obstructive Pulmonary DiseaseHyperinflation

Interventions

DRUG

Budesonide/Glycopyrronium/Formoterol Fumarate

BGF will be administered as 2 inhalations via oral route of administration

DRUG

Placebo

Matching placebo will be administered as 2 inhalations via oral route of administration

DEVICE

Metered dose inhaler

Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.